Company profile
Home - Scarlet Theraputics
A leader in red blood cell-based therapeutics. Scarlet Therapeutics is developing a pioneering platform that generates novel red blood cell-based therapeutics (tRBCs) to potentially treat a wide range of diseases.
Financial period: 1 Aug 2024 to 31 Jul 2025
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
MA | Transaction MzUxMTkzNzM5M2FkaXF6a2N4 | Paper/PDF filed
Published 07 Apr 2026 23:04
RESOLUTIONS | Transaction WUVZRkZBTE1hZGlxemtjeA | Paper/PDF filed
Published 07 Apr 2026 22:59
Last accounts made up date
Last confirmation statement made up date
RESOLUTIONS | Transaction WURGWEVKS0FhZGlxemtjeA | Paper/PDF filed
Published 26 Nov 2024 10:25
AA | Transaction MzQ0NDI2MjgxN2FkaXF6a2N4
Published 20 Nov 2024 11:03
SH01 | Transaction MzQ0MzU4MTA2NWFkaXF6a2N4
Published 15 Nov 2024 02:53
Company registered at Companies House
Scarlet Therapeutics develops engineered red blood cell-based therapeutics for a range of disease applications.
Reb blood cell-based novel therapeutics
None yet
1 May 2024 to 31 Jan 2026
Scarlet Therapeutics (Lead) is developing a pioneering platform that generates novel therapeutic red blood cells (tRBCs) to potentially treat a wide range of diseases. Red blood cells (RBC), which naturally circulate throughout the body, have a lifespan of up to 120 days. Therefore a therapy based on freshly produced tRBCs offers the potential for a long-...
1 Sep 2023 to 28 Feb 2025
Vast research and development spend is funnelled into next generation therapeutics - with gene therapy applications leading the field. Gene therapy is applicable to monogenic diseases but is more difficult to apply to more complex diseases that can arise due to alterations in more than one gene. Recombinant proteins are potentially an ideal modality for t...
